|Articles|August 1, 2002

August 2002
Volume 8
Issue 8

The Comparative Clinical and Economic Benefits of Drugs Should be Established and Discussed as Part of any Formulary Decision Process

Author(s)Mary S. Richardson, PharmD, Brian W. Bowers, PharmD, Jonathan L. Petrie, MD. Author Reply by Lisa K. Mannix, MD

Articles in this issue

about 24 years ago

Article

A New Era of Leadership

about 24 years ago

Article

The Potential of Pill Splitting to Achieve Cost Savings

about 24 years ago

Article

Rational Use of Antibiotics to Treat Respiratory Tract Infections

about 24 years ago

Article

Reducing Cesarean Delivery Rates in Managed Care Organizations

about 24 years ago

Article

Recombinant Human Erythropoietin Usage in a Large Academic Medical Center

about 24 years ago

Article

Coronary Artery Bypass Grafting in Octogenarians: Clinical and Economic Outcomes at Community-Based Healthcare Facilities

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Predicting GLP-1 Discontinuation From Pharmacy Claims

ByAayush Sisodia, MSHI, BDS

Published: August 6th 2026 | Updated: August 31st 2026

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

The Comparative Clinical and Economic Benefits of Drugs Should be Established and Discussed as Part of any Formulary Decision Process

Articles in this issue

Related Content

Predicting GLP-1 Discontinuation From Pharmacy Claims

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Trending on AJMC

FDA Approves Moderna’s mRNA Flu Vaccine After Phase 3 Success

CANN Responds to HRSA's Revised 340B Rebate Model Pilot

Setting Treatment Goals in RA: Remission, Joint Damage, and Systemic Risk

Predicting GLP-1 Discontinuation From Pharmacy Claims

Avoiding TNF Cycling: When to Switch Drug Classes in Rheumatoid Arthritis

A Look at PBM Reform and Transparency: Payer, Provider and Patient Impact

The Comparative Clinical and Economic Benefits of Drugs Should be Established and Discussed as Part of any Formulary Decision Process

Articles in this issue

Related Content

Predicting GLP-1 Discontinuation From Pharmacy Claims

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Trending on AJMC

FDA Approves Moderna’s mRNA Flu Vaccine After Phase 3 Success

CANN Responds to HRSA's Revised 340B Rebate Model Pilot

Setting Treatment Goals in RA: Remission, Joint Damage, and Systemic Risk

Predicting GLP-1 Discontinuation From Pharmacy Claims

Avoiding TNF Cycling: When to Switch Drug Classes in Rheumatoid Arthritis